Loratadine ATC Code: Understanding its Effects and Mechanism of Action

Loratadine, a tricyclic antihistamine with selective, peripheral H1-receptor activity, has been widely studied for its effectiveness in managing chronic idiopathic urticaria (CIU) and allergic rhinitis (AR). In controlled clinical trials involving over 10,000 subjects, loratadine 10 mg tablets once daily have demonstrated superior results in reducing associated itching, erythema, and hives compared to placebo.

In studies conducted among patients with CIU aged 12 years and older, the incidence of somnolence was similar to that of placebo. Additionally, loratadine was found to be comparable to clemastine in improving nasal and non-nasal symptoms of AR, while being superior to placebo.

The antihistamine effects of loratadine were seen within 1-3 hours following a single 10 mg dose, reaching a peak at 8-12 hours and lasting for more than 24 hours. Notably, loratadine does not inhibit norepinephrine uptake, has practically no influence on cardiovascular function or intrinsic cardiac pacemaker activity, and exhibits no significant H2-receptor activity.

Furthermore, during long-term treatment, there were no clinically significant changes observed in vital signs, laboratory test values, physical examinations, or electrocardiograms. Loratadine's mechanism of action is attributed to its selective peripheral H1-receptor antagonism, making it an effective and safe treatment option for patients suffering from CIU and AR.

Overall, the ATC code R06AX13 assigned to loratadine reflects its classification as a tricyclic antihistamine with selective, peripheral H1-receptor activity. With its proven efficacy and favorable safety profile, loratadine remains a trusted treatment choice for healthcare professionals and patients alike.

Loratidine atc code